New Antimicrobial Strategies to Treat Multi-Drug Resistant Infections Caused by Gram-Negatives in Cystic Fibrosis.

Autor:	Scoffone VC; Department of Biology and Biotechnology 'Lazzaro Spallanzani', University of Pavia, 27100 Pavia, Italy., Barbieri G; Department of Biology and Biotechnology 'Lazzaro Spallanzani', University of Pavia, 27100 Pavia, Italy., Irudal S; Department of Biology and Biotechnology 'Lazzaro Spallanzani', University of Pavia, 27100 Pavia, Italy., Trespidi G; Department of Biology and Biotechnology 'Lazzaro Spallanzani', University of Pavia, 27100 Pavia, Italy., Buroni S; Department of Biology and Biotechnology 'Lazzaro Spallanzani', University of Pavia, 27100 Pavia, Italy.
Jazyk:	angličtina
Zdroj:	Antibiotics (Basel, Switzerland) [Antibiotics (Basel)] 2024 Jan 11; Vol. 13 (1). Date of Electronic Publication: 2024 Jan 11.
DOI:	10.3390/antibiotics13010071
Abstrakt:	People with cystic fibrosis (CF) suffer from recurrent bacterial infections which induce inflammation, lung tissue damage and failure of the respiratory system. Prolonged exposure to combinatorial antibiotic therapies triggers the appearance of multi-drug resistant (MDR) bacteria. The development of alternative antimicrobial strategies may provide a way to mitigate antimicrobial resistance. Here we discuss different alternative approaches to the use of classic antibiotics: anti-virulence and anti-biofilm compounds which exert a low selective pressure; phage therapies that represent an alternative strategy with a high therapeutic potential; new methods helping antibiotics activity such as adjuvants; and antimicrobial peptides and nanoparticle formulations. Their mechanisms and in vitro and in vivo efficacy are described, in order to figure out a complete landscape of new alternative approaches to fight MDR Gram-negative CF pathogens.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu